Ambition 7
Research type
Research Study
Full title
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
IRAS ID
1013989
Contact name
Clinical Transparency
Contact email
Sponsor organisation
Novo Nordisk A/S
Clinicaltrials.gov Identifier
Research summary
Type 2 diabetes is an illness where the body cannot use insulin properly or does not make enough
insulin. The body needs insulin to use sugar and store energy. People with type 2 diabetes have too high blood sugar and often excess body weight. Zenagamtide is a new medicine that helps the body make more insulin and regulate appetite, which helps to lower blood sugar levels and body weight. In this study, researchers will look at how well zenagamtide lowers blood sugar levels, body weight and the risk of death due to heart disease compared to an already approved medicine, insulin glargine, in people with type 2 diabetes and a higher risk of heart disease.
Around 1778 participants, 45 years or older, across the world will take part in the study. All participants will have had type 2 diabetes for at least 6 months, blood sugar that is not well controlled despite taking 1–3 approved diabetes medicines, and a higher risk of diseases that affect the heart and blood vessels. A person is not allowed to take part in the study, if he/she gets severe low blood sugar levels or cannot recognize the signs of low blood sugar, has severe diseases of the kidneys and eyes, or is pregnant, breastfeeding, or planning to become pregnant.
During the first 3 weeks, the
participants are checked to make sure they can take part in the study. For the next up to 8 months, doctors will slowly increase the dose of the study medicine to the target dose. After a total of up to approximately 2 years, the participants will finish taking zenagamtide or insulin glargine. The participants’ health will be checked for 4 weeks after they stop taking the study medicine.
Both secoundary care and primary care sites within the UK will take part in this study.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
26/SC/0145
Date of REC Opinion
29 Jul 2026
REC opinion
Further Information Favourable Opinion